GRYSKA DAVID W 4

What Happened David W. Gryska, a member of the board of directors of Definium Therapeutics, was awarded two equity grants on June 11, 2026: 4,666 restricted stock units (RSUs) and a 19,188-share derivative award (stock option). Both awards were reported as grants at $0.00 per share (no cash paid at grant). These are awards/compensation grants (code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-11; Form 4 filed 2026-06-15 (filed within required two business days).
• Consideration: both grants reported at $0.00 (no cash paid at grant).
• Vesting: RSUs and the stock option vest 1/12th on each monthly anniversary of the grant date; if the company’s next annual meeting occurs before the first anniversary, any unvested awards will vest immediately prior to that meeting, subject to continued service (see footnotes F1 and F2).
• Shares owned following the transaction: not disclosed in the provided filing excerpt.
• Nature of transaction: award/grant (compensation), not an exercise-and-sale or market trade.

Context These grants are routine director/executive compensation and are contingent on continued service and the stated vesting schedule. The 19,188-share entry is a derivative (stock option) award that vests monthly per the footnote; it was granted, not exercised, so no immediate share sale or cashless exercise occurred. Awards reported at $0 are common for equity compensation and do not by themselves indicate buying or selling intent.